Limited Sampling and Dose Prediction Model for Cisplatin Using a Bayesian Approach

References

• Campbell B. A., Kalman S. M., Jacobs C. Plasma platinum levels: relationship to cisplatin dose and nephrotoxicity. Cancer Treat. Rep. 1983; 67: 169–172
   PubMedGoogle Scholar
• Collery P., Morel M., Millart H., Desoize B., Cossart C., Perdu D., Vallerand H., Bouana J. C., Pechery C., Etienne J. C., Choisy H., Dubois J. M. Oral administration of gallium in conjunction with platinum in lung cancer treatment. Metal Ions in Biology and Medicine, P Collery, L A Poirier, M Manfait, et al. J. Libbey, London, 437–42, 3990
   Google Scholar
• Crom W., Mauer E., Greene W., McHaney V., Hayes F., Green A., Evans W. Relation between cisplatin cytotoxicity and platinum accumulation in plasma. Proc. Am. Soc. Clin. Oncol. 1984; 3: 28
   Google Scholar
• De Gaeff A., Slebos R. J.C., Rodenhuis S. Resistance to cisplatin and analogues: mechanisms and potential clinical implications. Cancer Chemother. Pharmacol 1990; 22: 325–332
   Web of Science ®Google Scholar
• Desoize B., Maréchal F., Millart H., Cattan A. Correlation of clinical pharmacokinetic parameters of cisplatin with efficacy and toxicity. Biomed. Pharmacother. 1991; 45: 203–207
   PubMed Web of Science ®Google Scholar
• Kelsen D. P., Alcock N., Young C. W. Cisplatin nephrotoxicity. Correlation with plasma concentrations. Am. J. Clin. Oncol 1985; 8: 77–80
   PubMed Web of Science ®Google Scholar
• Reece P. A., Stafford I., Russel J., Khan M., Gill P. G. Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin. J. Clin. Oncol 1987; 5: 304–309
   PubMed Web of Science ®Google Scholar
• Vermoken J. B., van der Vijgh W. J.F., Klein I., Gall H. E., van Groeningen C. J., Hart G. A.M., Pinedo H. M. Pharmacokinetics of free and total platinum species after rapid and prolonged infusions of cisplatin. Clin. Pharmacol. ther. 1986; 39: 136–144
   PubMed Web of Science ®Google Scholar
• Thomas D. J., Clifford S. C., Neal D. E., Newel D. R. Pharmacokinetic and pharmacodynamic parameters of cisplatin in combination therapy for transitional cell carcinoma of the bladder. Br. J. Cancer 1993; 67(supp 20)38
   Google Scholar
• Favre R., Charbit M., Rinaldi Y. A., Iliadis A., Cano J. P., Carcasonne Y. Optimization of cisplatin dosage regimen administered by continuous 5 day infusion using Bayesian estimation. Proc. Am. Assoc. Cancer Res. 1987; 28: 434
   Web of Science ®Google Scholar
• Sheiner L. B., Beal S., Rosenberg B., Marathe V. V. Forecasting individual pharmacokinetics. Clin. Pharmacol. ther. 1979; 26: 194–205
   Web of Science ®Google Scholar
• Bannister S. J., Chang Y., Sternson L. A., Repta A. J. Atomic absorption spectrophotometry of free circulating platinum species in plasma derived from cis-dichlorodiammineplatinum(II). Clin. Chem. 1978; 24: 877–880
   PubMed Web of Science ®Google Scholar
• Gibaldi M., Perrier D. Drugs and the Pharmaceutical Sciences, vol. 15 Pharmacokinetics, 2nd ed. M. Dekker Inc, New-York 1982; 71
   Google Scholar
• Dobbs N. A., Twelves C. J., Ramirez A. J., Towlson K., Richards M. A. Practical implications and acceptability of pharmacokinetic studies in women with advanced cancer. Br. J. Cancer 1993; 67(supp 20)64
   Google Scholar
• Riley C. M., Sternson L. A. Cisplatin. Analyt. Prof. Drug. Subst. 1985; 14: 77–105
   Google Scholar
• Reece P. A., Stafford I., Davy M., Morris R., Freeman S. Influence of infusion time on unchanged cisplatin disposition in patients with ovarian cancer. Cancer Chemother. Pharmacol. 1989; 24: 256–260
   PubMed Web of Science ®Google Scholar
• Iliadis A., Bachir-Rako M., Bruno R., Favre R. Bayesian estimation and clearance prediction in high dose methotrexate infusions. J. Pharmacokinet. Biopharm. 1985; 13: 101–115
   PubMedGoogle Scholar
• Launay M. C., Milano G., Iliadis A., Frenay M., Namer N. A limited sampling procedure for estimating adriamycin pharmacokinetic parameters in cancer patients. Br. J. Cancer 1989; 60: 89–92
   PubMed Web of Science ®Google Scholar
• Ratain M. J., Robert J., Van der Vijgh W. J.F. Limited sampling models for doxorubicin pharmacokinetics. J. Clin. Oncol. 1991; 9: 871–876
   PubMed Web of Science ®Google Scholar
• Egorin M. J., Forrest A., Belami C. P., Ratain M. J., Abrams J. S., Van Echo D. A. A limited sampling strategy for cyclophosphamide pharmacokinetics. Cancer Res. 1989; 49: 3129–3133
   PubMed Web of Science ®Google Scholar